News articles about Boston Scientific (NYSE:BSX) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Boston Scientific earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave press coverage about the medical equipment provider an impact score of 45.3483925126218 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media headlines that may have effected Accern Sentiment’s scoring:
- Boston Scientific’s Positive SCS Trial Aids Neuromodulation (zacks.com)
- Boston Scientific's Positive SCS Trial Aids Neuromodulation (finance.yahoo.com)
- Boston Scientific (BSX) Reports Positive Results from WHISPER Spinal Cord Stimulation Study (streetinsider.com)
- Boston Scientific (BSX) Reports FDA Approval for Spectra WaveWriter Spinal Cord Stimulator (streetinsider.com)
- Boston Scientific Corporation: Boston Scientific Announces Positive Results from WHISPER Spinal Cord Stimulation Study (twst.com)
A number of equities analysts have recently weighed in on BSX shares. Stifel Nicolaus reissued a “buy” rating and issued a $32.00 price target on shares of Boston Scientific in a report on Monday, September 25th. SunTrust Banks reaffirmed a “buy” rating and issued a $34.00 price objective on shares of Boston Scientific in a research report on Monday, October 2nd. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Boston Scientific in a research report on Tuesday, October 3rd. BMO Capital Markets reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Boston Scientific in a research report on Friday, October 13th. Finally, Zacks Investment Research downgraded Boston Scientific from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $31.00.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same quarter in the previous year, the business earned $0.27 earnings per share. The firm’s quarterly revenue was up 5.6% compared to the same quarter last year. research analysts forecast that Boston Scientific will post 1.25 earnings per share for the current year.
In other Boston Scientific news, EVP Michael P. Phalen sold 15,835 shares of the business’s stock in a transaction dated Saturday, December 29th. The stock was sold at an average price of $25.25, for a total transaction of $399,833.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the stock in a transaction on Tuesday, November 28th. The shares were purchased at an average cost of $0.45 per share, with a total value of $183,602.70. In the last three months, insiders have sold 96,585 shares of company stock valued at $2,578,197. 0.74% of the stock is owned by company insiders.
Boston Scientific Company Profile
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
What are top analysts saying about Boston Scientific? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Boston Scientific and related companies.